drugset / Trial / NCT06281106
TYK2 Inhibition in Paradoxical Psoriasis
Phase 2/3
Terminated
2 enrolled
Prof Curdin Conrad
Centre Hospitalier Universitaire Vaudois · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Paradoxical psoriasis is a side effect of a biological treatment (anti-tumor necrosis factor agent, short called anti-TNF) that is used to treat diseases of the skin, the intestine or the joints. If paradoxical psoriasis occurs, the anti-TNF-treatment often needs to be stopped and so far, no specific treatment for paradoxical psoriasis exists. This research project aims to study whether the efficacy of the drug 'Deucravacitinib' 6mg, a tablet taken by mouth once a day is superior compared to taking a placebo in treating paradoxical psoriasis.
Timeline
- Start
- 2024-06-20
- Primary completion
- 2025-03-20
- Completion
- 2025-03-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | CRAVACITINIB | Small molecule | 6 mg | Oral |